PRCT logo

PROCEPT BIOROBOTICS CORP

PRCTNASDAQ
🏆 #2485 by market capEarnings Oct 29 · PostUS Equity
$368.26▲ $0.44 (+0.12%)
Simulated price
🔔
Track PRCT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.1%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$988M
Small Cap
📈Revenue Growth (YoY)
+22.7%
Healthy
📊Gross Margin
64.2%
High
💵FCF Margin
—
⚖️P/S Ratio
2.9x
Cheap
Otter Score
60
Fair
No chart data available for PRCT.

Trading Snapshot

Day Range
$364.71 – $372.39
52-Week Range
$16.67 – $38.11
Volume
$5.48B
Avg Volume
$4.75B
Shares Outstanding
56.9M
Next Earnings
Dec 3, 2026

Fundamentals Snapshot

Annual Revenue
$308M
Last Q Revenue
$94M
P/E Ratio
—
P/S Ratio
2.9x
EPS (TTM)
$-1.95
Dividend Yield
—
Dilution (1yr)
+4.1%

Why Investors Own PRCT

  • ✓High-growth profile — revenue up +55.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 71% gross margin and 15% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PRCT logo

PROCEPT BIOROBOTICS CORP

PRCT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$308M▲ +37.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
63.7%▲ +4.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$104M▲ +7.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$58M▼ −43.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
56.1M▲ +4.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$208M▼ −$45M YoY
StockOtter · stockotter.space

About PROCEPT BIOROBOTICS CORP

PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Ratings

ⓘ
Consensus
Buy
21 analysts
Strong Buy3
Buy7
Hold10
Sell1
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

PROCEPT BIOROBOTICS CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift PRCT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

PROCEPT BIOROBOTICS CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.